An inspiring play about Parkinson’s and Parkour is coming to a theatre near you
Author: Geoffrey ChangPublished: 8 September 2016
Prep: Cook: Serves:
A new thought-provoking play that explores the friendship between a free-running teenager and a woman with early-onset Parkinson’s is going on a nationwide tour
After three sell-out shows in cities across the UK and rave reviews, a new Parkinson’s play called Kinetics is taking to the road for a run of 13 performances throughout September and October.
Based on a true story, the inspiring theatre piece explores the unlikely friendship between a teenage boy who is devoted to free running (Parkour) – the extreme sport that involves navigating obstacles without equipment – and a middle-aged woman with early-onset Parkinson’s disease.
But what can they possibly have in common? Despite living completely opposing lives, a chance encounter leads the two protagonists to realise the answer: they share the desire to move.
Featuring projected imagery and electrifying live Parkour, the show raises awareness of Parkinson’s with wit, while challenging perceptions and giving a realistic insight into the daily struggles that come with living with the condition.
Written by actor and drama teacher, Sue Wylie, the play recounts her personal experience of living with Parkinson’s. Sue, who performs the lead role, explains: “Five years ago shortly after my 50th birthday I was diagnosed with Parkinson’s. After the initial shock I knew I wanted to write about it. I was teaching drama at the time and discovered that a bright but rebellious 16-year-old student in my tutor group was free running on the school roof.
“I was intrigued by the risks he took in his addiction to this extreme sport. How interesting to contrast that with a middle-aged woman whose world of movement is slowly being eroded. What if their paths should accidentally cross and a friendship form? I knew there was a story in there and so Kinetics was born.”
Sue Wylie (left) playing lead character Rose
Through the juxtaposition of the characters the sharp script, full of emotion and humour, unexpectedly draws parallels between two lives that couldn’t seem more opposite. The two learn more important life lessons from one another than they ever could have imagined.
Following the initial success of sold out shows last year, Kinetics received funding from the Arts Council, allowing them to organise the upcoming Autumn 2016 tour. Parkinson’s UK have officially endorsed the play with CEO Steve Ford saying: “Sue’s play offers an inspiring story to which we can all relate.”
After his emotional appeal, we look at Billy's top fundraising moments
2 days ago
Musical therapy study to receive $20 million in funding
The National Institutes of Health (NIH) is donating US $20 million to a medical trial researching the effects of musical therapy on brain conditions, including Parkinson’s. The trial will be carried out by the Sound Health initiative, a joint partnership between the NIH and The John F Kennedy Center for the Performing Arts. The initiative was created to expand current knowledge of how listening, performing and creating music could be harnessed for health and wellness. Francis S. Collins, director of the NIH, said: “We know that the beat of a metronome can steady the gait of someone with Parkinson’s disease, for example, but we don’t fully understand how that happens. “If we can pinpoint in the brain how music therapy works through the use of imaging and biomarkers, the hope is that we can improve its effectiveness and apply it more broadly to improve the lives of millions of people.”
Researchers develop automated system to diagnose Parkinson’s
In an international study, researchers from the US, Germany and Austria have used a non-invasive MRI method to develop an automated system that can diagnose Parkinson’s. As part of the study – published in medical journal ‘The Lancet Digital Health’ – researchers worked with 1,002 patients and used an imaging method that measures how water molecules diffuse in the brain. This helped them to identify where neurodegeneration is occurring. Researchers hope this will help improve the accuracy of early Parkinson’s diagnoses – which they estimate to be around 58%. Dr David Vaillancourt, who led the study, said: “Our method may help to reduce the number of misdiagnosed cases in the future. Since these diseases require unique treatment plans and different medications, and clinical trials testing new medications require the correct diagnosis, getting it right is important for patient care.”
MJFF announces $10 million competition for Parkinson’s
The Michael J Fox Foundation has launched the ‘Ken Griffin Alpha-synuclein Imaging Competition’ – a US $10 million programme aiming to develop a game-changing tool for Parkinson’s research. As part of the competition, participating teams will compete in a scientific race to build a device that is able to identify alpha-synuclein – a protein closely associated with Parkinson’s. Although almost everyone diagnosed with Parkinson’s has clumps of alpha-synuclein in the brain, these are currently only visible when analysing tissue during autopsies. The competition is named after Ken Griffin, CEO of US investment firm Citadel who has given US $7.5 million funding to the programme. Griffin – whose father has Parkinson’s – said: “If we have the imaging capability to observe the pathology that arises from protein-misfolding in real time, and understand how drugs are impacting people in real time, that would be a major advance.”